We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02861534




Registration number
NCT02861534
Ethics application status
Date submitted
5/08/2016
Date registered
5/08/2016
Date last updated
13/12/2018

Titles & IDs
Public title
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
Scientific title
A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)
Secondary ID [1] 0 0
2016-000671-25
Secondary ID [2] 0 0
1242-001
Universal Trial Number (UTN)
Trial acronym
VICTORIA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Heart Failure 0 0
Chronic Heart Failure With Reduced Ejection Fraction 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Vericiguat
Treatment: Drugs - Placebo for Vericiguat

Experimental: Vericiguat - Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be uptitrated to 5 mg and to 10 mg.

Placebo Comparator: Placebo - Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be uptitrated to 5 mg and to 10 mg.


Treatment: Drugs: Vericiguat
2.5, 5.0, or 10.0 mg orally once daily

Treatment: Drugs: Placebo for Vericiguat
2.5, 5.0, or 10.0 mg orally once daily

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure Hospitalization
Timepoint [1] 0 0
Up to approximately 3.5 years
Secondary outcome [1] 0 0
Time to the First Occurrence of CV Death
Timepoint [1] 0 0
Up to approximately 3.5 years
Secondary outcome [2] 0 0
Time to the First Occurrence of HF Hospitalization
Timepoint [2] 0 0
Up to approximately 3.5 years
Secondary outcome [3] 0 0
Time to Total HF Hospitalizations (including frst and recurrent events)
Timepoint [3] 0 0
Up to approximately 3.5 years
Secondary outcome [4] 0 0
Time to First Occurrence of Composite Endpoint of All-cause Mortality or HF Hospitalization
Timepoint [4] 0 0
Up to approximately 3.5 years
Secondary outcome [5] 0 0
Time to All-cause Mortality
Timepoint [5] 0 0
Up to approximately 3.5 years

Eligibility
Key inclusion criteria
- History of chronic HF (New York Heart Association [NYHA] Class II-IV) on standard
therapy before qualifying HF decompensation

- Previous HF hospitalization within 6 months prior to randomization or intravenous (IV)
diuretic treatment for HF (without hospitalization) within 3 months.

- Brain natriuretic peptide (BNP) levels: sinus rhythm-= 300 pg/mL; atrial
fibrillation-= 500 pg/mL and N-terminal pro-Brain Natriuretic Peptide (NT-proBNP)
levels: sinus rhythm- = 1000 pg/mL; atrial fibrillation - = 1600 pg/mL within 30 days
prior to randomization

- Left ventricular ejection fraction (LVEF) of <45% assessed within 12 months prior to
randomization by any method

- If female, is not of reproductive potential or agrees to avoid becoming pregnant while
receiving study drug and for 14 days after the last dose of study drug by complying
with one of the following: practice abstinence from heterosexual activity or use (or
have her partner use) acceptable contraception during heterosexual activity.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Clinically unstable at the time of randomization as defined by either the
administration of any IV treatment within 24 hours prior to randomization, and/or
systolic blood pressure (SBP) <100 mmHg or symptomatic hypotension

- Current or anticipated use of long-acting nitrates or nitric oxide (NO) donors
including isosorbide dinitrate, isosorbide 5-mononitrate, pentaerythritol
tetranitrate, nicorandil or transdermal nitroglycerin (NTG) patch, and molsidomine

- Current or anticipated use of phosphodiesterase type 5 (PDE5) inhibitors such as
vardenafil, tadalafil, and sildenafil

- Current use or anticipated use of a soluble guanylate cyclase (sGC) stimulator such as
riociguat

- Known allergy or sensitivity to any sGC stimulator

- Awaiting heart transplantation (United Network for Organ Sharing Class 1A / 1B or
equivalent), receiving continuous IV infusion of an inotrope, or has/anticipates
receiving an implanted ventricular assist device

- Primary valvular heart disease requiring surgery or intervention, or is within 3
months after valvular surgery or intervention

- Hypertrophic obstructive cardiomyopathy

- Acute myocarditis, amyloidosis, sarcoidosis, Takotsubo cardiomyopathy

- Post-heart transplant cardiomyopathy

- Tachycardia-induced cardiomyopathy and/or uncontrolled tachyarrhythmia

- Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction
[NSTEMI], or ST elevation myocardial infarction [(STEMI]) or coronary
revascularization (coronary artery bypass grafting [CABG] or percutaneous coronary
intervention [PCI]) within 60 days, or indication for coronary revascularization at
time of randomization

- Symptomatic carotid stenosis, transient ischemic attack (TIA) or stroke within 60 days

- Complex congenital heart disease

- Active endocarditis or constrictive pericarditis

- Estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m2 or chronic dialysis

- Severe hepatic insufficiency such as with hepatic encephalopathy

- Malignancy or other non-cardiac condition limiting life expectancy to <3 years

- Require continuous home oxygen for severe pulmonary disease

- Current alcohol and/or drug abuse

- Participated in another interventional clinical study and treatment with another
investigational product =30 days prior to randomization or plans to participate in any
other trial/investigation during the duration of this study

- Mental or legal incapacitation and is unable to provide informed consent

- Immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is
involved with this study

- Interstitial Lung Disease

- Is pregnant or breastfeeding or plans to become pregnant or to breastfeed during the
course of the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Merck Sharp & Dohme - North Ryde
Recruitment postcode(s) [1] 0 0
- North Ryde
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Alaska
Country [3] 0 0
United States of America
State/province [3] 0 0
Arizona
Country [4] 0 0
United States of America
State/province [4] 0 0
Arkansas
Country [5] 0 0
United States of America
State/province [5] 0 0
California
Country [6] 0 0
United States of America
State/province [6] 0 0
Colorado
Country [7] 0 0
United States of America
State/province [7] 0 0
District of Columbia
Country [8] 0 0
United States of America
State/province [8] 0 0
Florida
Country [9] 0 0
United States of America
State/province [9] 0 0
Georgia
Country [10] 0 0
United States of America
State/province [10] 0 0
Idaho
Country [11] 0 0
United States of America
State/province [11] 0 0
Illinois
Country [12] 0 0
United States of America
State/province [12] 0 0
Indiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Iowa
Country [14] 0 0
United States of America
State/province [14] 0 0
Kentucky
Country [15] 0 0
United States of America
State/province [15] 0 0
Louisiana
Country [16] 0 0
United States of America
State/province [16] 0 0
Maine
Country [17] 0 0
United States of America
State/province [17] 0 0
Maryland
Country [18] 0 0
United States of America
State/province [18] 0 0
Massachusetts
Country [19] 0 0
United States of America
State/province [19] 0 0
Michigan
Country [20] 0 0
United States of America
State/province [20] 0 0
Minnesota
Country [21] 0 0
United States of America
State/province [21] 0 0
Mississippi
Country [22] 0 0
United States of America
State/province [22] 0 0
Missouri
Country [23] 0 0
United States of America
State/province [23] 0 0
Montana
Country [24] 0 0
United States of America
State/province [24] 0 0
Nebraska
Country [25] 0 0
United States of America
State/province [25] 0 0
Nevada
Country [26] 0 0
United States of America
State/province [26] 0 0
New Jersey
Country [27] 0 0
United States of America
State/province [27] 0 0
New Mexico
Country [28] 0 0
United States of America
State/province [28] 0 0
New York
Country [29] 0 0
United States of America
State/province [29] 0 0
North Carolina
Country [30] 0 0
United States of America
State/province [30] 0 0
Ohio
Country [31] 0 0
United States of America
State/province [31] 0 0
Oklahoma
Country [32] 0 0
United States of America
State/province [32] 0 0
Pennsylvania
Country [33] 0 0
United States of America
State/province [33] 0 0
Rhode Island
Country [34] 0 0
United States of America
State/province [34] 0 0
South Carolina
Country [35] 0 0
United States of America
State/province [35] 0 0
Tennessee
Country [36] 0 0
United States of America
State/province [36] 0 0
Texas
Country [37] 0 0
United States of America
State/province [37] 0 0
Utah
Country [38] 0 0
United States of America
State/province [38] 0 0
Virginia
Country [39] 0 0
United States of America
State/province [39] 0 0
Wisconsin
Country [40] 0 0
Argentina
State/province [40] 0 0
Buenos Aires
Country [41] 0 0
Austria
State/province [41] 0 0
Vienna
Country [42] 0 0
Chile
State/province [42] 0 0
Santiago
Country [43] 0 0
China
State/province [43] 0 0
Beijing
Country [44] 0 0
Colombia
State/province [44] 0 0
Bogota
Country [45] 0 0
Czechia
State/province [45] 0 0
Prague
Country [46] 0 0
Denmark
State/province [46] 0 0
Glostrup
Country [47] 0 0
Finland
State/province [47] 0 0
Espoo
Country [48] 0 0
France
State/province [48] 0 0
Paris
Country [49] 0 0
Germany
State/province [49] 0 0
Haar
Country [50] 0 0
Greece
State/province [50] 0 0
Alimos
Country [51] 0 0
Hong Kong
State/province [51] 0 0
Hong Kong
Country [52] 0 0
Hungary
State/province [52] 0 0
Budapest
Country [53] 0 0
Ireland
State/province [53] 0 0
Dublin
Country [54] 0 0
Israel
State/province [54] 0 0
Hod Hasharon
Country [55] 0 0
Italy
State/province [55] 0 0
Rome
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Seoul
Country [57] 0 0
Malaysia
State/province [57] 0 0
Petaling Jaya
Country [58] 0 0
Mexico
State/province [58] 0 0
Mexico City
Country [59] 0 0
Netherlands
State/province [59] 0 0
Haarlem
Country [60] 0 0
New Zealand
State/province [60] 0 0
Wellington
Country [61] 0 0
Norway
State/province [61] 0 0
Drammen
Country [62] 0 0
Peru
State/province [62] 0 0
Lima
Country [63] 0 0
Philippines
State/province [63] 0 0
Makati
Country [64] 0 0
Poland
State/province [64] 0 0
Warsaw
Country [65] 0 0
Puerto Rico
State/province [65] 0 0
Bayamon
Country [66] 0 0
Puerto Rico
State/province [66] 0 0
Caguas
Country [67] 0 0
Puerto Rico
State/province [67] 0 0
Humacao
Country [68] 0 0
Puerto Rico
State/province [68] 0 0
Ponce
Country [69] 0 0
Puerto Rico
State/province [69] 0 0
San Juan
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Moscow
Country [71] 0 0
Singapore
State/province [71] 0 0
Singapore
Country [72] 0 0
South Africa
State/province [72] 0 0
Midrand
Country [73] 0 0
Spain
State/province [73] 0 0
Madrid
Country [74] 0 0
Switzerland
State/province [74] 0 0
Lucerne 6
Country [75] 0 0
Taiwan
State/province [75] 0 0
Taipei
Country [76] 0 0
Turkey
State/province [76] 0 0
Istanbul
Country [77] 0 0
Ukraine
State/province [77] 0 0
Kiev
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Hoddesdon

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merck Sharp & Dohme Corp.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Bayer
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Canadian VIGOUR Centre
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
Duke Clinical Research Institute
Address [3] 0 0
Country [3] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event
driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is
vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the
composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants
with HFrEF.
Trial website
https://clinicaltrials.gov/show/NCT02861534
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Mahesh J. Patel, MD
Address 0 0
Merck Sharp & Dohme Corp.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Toll Free Number
Address 0 0
Country 0 0
Phone 0 0
1-888-577-8839
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT02861534